Skip to main
TECH
TECH logo

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is projected to generate revenues of $315.0 million, reflecting a 3% growth compared to the previous year, indicating stability and growth potential in its business segments. The firm's adjusted earnings are expected to increase slightly to $0.50 per share, up from $0.49 the prior year, showcasing operational efficiency and profitability. The company maintains a robust presence in key markets, with approximately 55% of its revenue derived from the United States, supporting a diversified global revenue stream that enhances its financial resilience.

Bears say

Bio-Techne's stock outlook is negatively affected by the escalation of US tariffs and proposed cuts of up to 40% in funding for US agencies, including the NIH, which are anticipated to significantly impact revenues and gross margins in the upcoming 4Q25E. The company's exposure to these external factors is expected to result in slower-than-expected revenue growth and profit margins for the current quarter ending June 30. This adjustment to revenue and margin estimates indicates a deterioration in financial performance expectations for the company.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.